Literature DB >> 212568

Genetic analyses of differences in incidence of mammary tumors and reticulum cell neoplasms with the use of recombinant inbred lines of mice.

A Dux, O Mühlbock, D W Bailey.   

Abstract

The influence of genes, in addition to genes in the H-2 complex, that effect the genesis of mammary tumors was studied. The recombinant inbred (RI) CXB lines were chosen for this investigation, because they are well suited for the study of the genetics of a trait for which the genotype affects probability of phenotype expression and which therefore is measured as incidence. Females of seven RI lines (CXBD, CXBE, CXBG, CXBH, CXBI, CXBJ, and CXBK) and their progenitor strains C57BL/6By (B6) and BALB/cBy (BALB/c) were given ip injections of MuMTV at 3 months of age and were force bred. They were observed for mammary tumors. The B6 strain was least susceptible, and mammary tumors appeared late in life. The BALB/c strain was most susceptible, and the tumors appeared early in life. The course of tumor development in the RI lines fell between these extremes. The RI strain distribution pattern of mammary tumor incidence indicated that at least one and probably several loci in addition to those at H-2 determined the difference between the BALB/c and B6 strains. Effects of the other gene(s) appeared to be even more important than those of H-2. The locations of those loci were not made clear by this study. The spontaneous incidence of reticulum cell neoplasms was also recorded. The most frequently formed neoplasm of the reticular system was a Hodgkin's-like lesion. The data suggested an influence of the H-2 complex.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 212568

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  9 in total

1.  Quantitative trait locus analysis using recombinant inbred intercrosses: theoretical and empirical considerations.

Authors:  Fei Zou; Jonathan A L Gelfond; David C Airey; Lu Lu; Kenneth F Manly; Robert W Williams; David W Threadgill
Journal:  Genetics       Date:  2005-05-06       Impact factor: 4.562

2.  Quantitative trait mapping in a diallel cross of recombinant inbred lines.

Authors:  Shirng-Wern Tsaih; Lu Lu; David C Airey; Robert W Williams; Gary A Churchill
Journal:  Mamm Genome       Date:  2005-05       Impact factor: 2.957

Review 3.  Natural and induced immunity to mouse mammary tumors and the mammary tumor virus (MuMTV).

Authors:  O Stutman
Journal:  Springer Semin Immunopathol       Date:  1982

4.  The polymorphism architecture of mouse genetic resources elucidated using genome-wide resequencing data: implications for QTL discovery and systems genetics.

Authors:  Adam Roberts; Fernando Pardo-Manuel de Villena; Wei Wang; Leonard McMillan; David W Threadgill
Journal:  Mamm Genome       Date:  2007-08-03       Impact factor: 2.957

5.  Propylnitrosourea-induced T-lymphomas in LEXF RI strains of rats: genetic analysis.

Authors:  L M Lu; H Shisa; J Tanuma; H Hiai
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

6.  Comparative study of the immunological characteristics of three different C57BL/6N mouse substrains.

Authors:  Jun Young Choi; Hye Ryeong Kim; Kil Soo Kim; Young-Suk Jung; Joon-Yong Cho; Dae Youn Hwang; Hyun Keun Song
Journal:  Lab Anim Res       Date:  2017-06-30

7.  Comparison of humoral and cell-mediated immunity in three different C57BL/6N mouse substrains.

Authors:  Hye Ryeong Kim; Jun Young Choi; Kil Soo Kim; Young-Suk Jung; Joon-Yong Cho; Dae Youn Hwang; Hyun Keun Song
Journal:  Lab Anim Res       Date:  2017-06-30

Review 8.  Use of C57BL/6N mice on the variety of immunological researches.

Authors:  Hyun Keun Song; Dae Youn Hwang
Journal:  Lab Anim Res       Date:  2017-06-30

9.  Irf3 polymorphism alters induction of interferon beta in response to Listeria monocytogenes infection.

Authors:  Oleg Garifulin; Zanmei Qi; Haihong Shen; Sujatha Patnala; Michael R Green; Victor Boyartchuk
Journal:  PLoS Genet       Date:  2007-07-20       Impact factor: 5.917

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.